Vogenx, Inc.

Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia and gastroparesis. The company's lead investigational product candidate, mizagliflozin, is a selective inhibitor of the sodium-glucose transporter 1, aimed at disorders related to glucose absorption and postprandial dysregulation.